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ABSTRACT
The urokinase receptor (u-PAR) which is largely
regulated at the transcriptional level has been
implicated in tumor progression. In this study, we
explored the epigenetic regulation of u-PAR and
showed that the histone variant H2A.Z negatively
regulates its expression in multiple cell lines.
Chromatin immunoprecipitation assays revealed
that H2A.Z was enriched at previously characterized
u-PAR-regulatory regions (promoter and a down-
stream enhancer) and dissociates upon activation
of gene expression by phorbol ester (PMA). Using
specific chemical and dominant negative expres-
sion constructs, we show that the MEK–ERK signal-
ing pathway terminating at AP-1 transcription
factors intersects with the epigenetic control of
u-PAR expression by H2A.Z. Furthermore, we dem-
onstrate that two other AP-1 targets (MMP9 gene
and miR-21 microRNA) are also H2A.Z regulated.
In conclusion, our work demonstrates that (i) the
expression of two genes and a microRNA all
implicated in tumor progression are directly
regulated by H2A.Z and (ii) MEK–ERK signaling
terminating at AP-1 intersects with the epigenetic
control of target gene expression by H2A.Z.
INTRODUCTION
The urokinase receptor (u-PAR), a 55–60kDa heavily
glycosylated disulfide-linked protein connected to the
cell surface via a glycolipid moiety (1), promotes tumor
progression. U-PAR is overexpressed in divergent tumors
types (2–6) and potentially represents a promising thera-
peutic target (7–13). This cell surface receptor promotes
tumor progression via multiple mechanisms. First, u-PAR
interacts with the extracellular domain of integrins to
regulate cell proliferation, cell attachment and tumor
dormancy (14–18). Second, high afﬁnity binding of the
serine protease urokinase (u-PA) with u-PAR converts
the inert plasminogen into the broadly acting plasmin at
a higher rate than ﬂuid phase reactants (19). Focusing of
proteolysis (via plasmin generation) at the cell surface
results in extracellular matrix degradation (14) thereby
facilitating tumor cell migration/invasion. Finally, it has
been shown that the seven trans-membrane receptor
FPR-like receptor-1/lipoxin A4 receptor, a G protein-
coupled receptor directly interacts with a soluble cleaved
form of u-PAR to induce chemotaxis (20).
u-PAR expression is, to a large extent, regulated at the
level of transcription (21–23) although mRNA stability
(22,24), protein translational efﬁciency (25) and turnover
(26) also contribute to the ﬁnal amount of protein
product. In regard to transcriptional control, the
promoter cis-elements and trans-acting factors regulating
u-PAR expression have been well-studied by our and
other groups (21,27–33). Of the transcription factors pre-
viously reported to be regulatory for u-PAR expression,
AP-1 and NF-kB modulate inducible expression by
diverse stimuli including epidermal growth factor (EGF),
transforming growth factor b type 1 (TGF-b1), phorbol-
12-myristate-13-acetate (PMA), interferons and a
mutation-activated K-Ras (21,27,31,32). In addition, we
recently reported on the role of an AP-1-harboring
intragenic enhancer in the regulation of both constitutive
and inducible u-PAR expression (33).
Although a substantial amount of work has been done
to identify the cis- and trans-acting factors regulating
u-PAR expression (21,27–33), the epigenetic regulation
of this gene is poorly understood. Previous studies have
identiﬁed a multitude of genes involved in tumor progres-
sion whose expression is regulated epigenetically (34–37).
Understanding the molecular mechanism of epigenetic
regulation of genes involved in cancer and metastasis
might, ultimately, lead to the development of drugs that
correct the expression of epigenetically dysregulated genes.
In light of the overwhelming evidence implicating u-PAR
in cancer progression, we undertook a study to determine
if, and how, u-PAR expression is epigenetically regulated.
We describe here a new mechanism of epigenetic regu-
lation of u-PAR and two other AP-1-regulated targets
(MMP-9, oncomiR-21) mediated by H2A.Z, a highly
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Histone variants differ from their canonical counterparts
in that the former are synthesized throughout the cell cycle
and deposited on DNA outside of S-phase (38). In this
study, we report the novel ﬁnding that H2A.Z is repressive
for the expression of u-PAR and two other AP-1-
regulated targets (MMP-9, oncomiR-21). Moreover,
induced expression of these three AP-1-regulated targets
requires H2A.Z eviction from the corresponding regula-




All the chemicals, antibodies and siRNA used in this study
are listed in Supplementary Table S1. Primers and
Taqman probes (Applied Biosystem) used in real time
PCR are listed in Supplementary Table S2. The Tam-67
vector, encoding a c-Jun protein lacking the transactiva-
tion domain (amino acids 3–122) has been described else-
where (39). The pBABE puro K-Ras V12 plasmid
encoding a constitutively active mutant K-Ras protein
(G12V mutation) was procured from Addgene (Catalog
No. 9052).
Tissue culture
All cancer cell lines were maintained in McCoy’s 5A media
containing 10% FBS and antibiotics (as required) in a
humidiﬁed incubator at 37 C with 5% CO2. For ChIP
assays, cultures were grown in 15-cm diameter plates to
60–70% conﬂuency. For inducing gene expression, PMA
was used in cultures at 100nM concentration.
Chromatin immunoprecipitation assay and quantitative
real-time PCR
The chromatin immunoprecipitation (ChIP) experiments
were performed using the ChIP-IT-Express kit from
Active Motif (Catalog No. 53009) according to the manu-
facturer’s instructions. Brieﬂy, cells were ﬁxed, DNA–
proteins cross-linked using 1% formaldehyde at room
temperature for 10min. Fixation was stopped by adding
glycine and the cells lysed. The DNA was subjected to
enzymatic digestion (using a micrococcal nuclease-
containing enzymatic cocktail from Active Motif
Catalog No. 53009) for 20–25min at 37 C to obtain
mostly mononucleosomes. The resulting chromatin prep-
aration was incubated at 4 C with the appropriate
antibody (3–8mg) and precipitated complexes washed
four times. Cross-linking was reversed by incubation at
65 C (4h). After digestion with Proteinase K (2h at
42 C), DNA was puriﬁed by ethanol extraction, air
dried and re-dissolved in H2O. The retrieved DNA was
then subjected to real-time RT–PCR ampliﬁcation using
speciﬁc primers (amplicon size 90–110bp) listed in
Supplementary Table S2 and a SYBR green qPCR
master mix (Applied Biosytem). Input (in each qRT–
PCR reaction) was used to normalize the values. All
ChIP assays were repeated twice and individual qPCR
reactions performed in triplicates with results presented
as average values±SD. The relative enrichment was
calculated as 2
Ct where Ct=Ct (Input)–Ct (ChIP).
RNA isolation and quantitative real-time PCR
Total RNA was isolated from cell culture using Trizol as
per the manufacturer’s instruction (Invitrogen).
Contaminating residual DNA was removed using the
TURBO DNA-free kit (Ambion, Catalog No. AM1907).
RNA (2mg) was used to prepare cDNA using the high
capacity cDNA reverse transcription kit as per the manu-
facturer’s instruction (Applied Biosytem cat # 4368814).
Taqman probes (Applied Biosystem) and real-time PCR
master mix (Applied Biosystem) were employed for
real-time PCR as per the manufacturer’s instruction. All
ampliﬁcations were carried out in triplicates. Data were
normalized using GAPDH or Actin.
Western blotting
Cell lysis and western blotting was performed as described
previously by us (26).
SiRNA knock downs and transient transfection
Lipofectamine 2000 was used for transfections with
plasmid DNA and siRNA following the manufacturer’s
instructions (Invitrogen). Cells were harvested after 48h
for RNA isolation or ChIP assays.
RESULTS
H2A.Z occupies the regulatory regions of u-PAR and is
evicted upon gene expression
In order to gain insight into the epigenetic regulation of
u-PAR expression, ChIP assays were employed in an
unbiased screen to identify histone modiﬁcations or
exchange of histone variants at the u-PAR promoter and
enhancer under conditions of gene activation. We elected
to use GEO colon cancer cells which express low endogen-
ous u-PAR levels but which can be rapidly induced for
transcription of this gene (23) with PMA (Figure 1B).
Quantitative real-time PCR (qPCR) was performed
using chromatin generated from either unstimulated or
PMA-stimulated GEO cells using primer sets correspond-
ing to the promoter, enhancer and intron 3 (Figure 1A and
C). While both the promoter and the enhancer were
enriched in acetylated histone 3 (H3-Ac) and acetylated
histone 4 (H4-Ac) as expected for a gene induced for ex-
pression, dimethylated histone 3 (at the arginine,
H3R2me2) was lost from the promoter, enhancer and
intron 3 of the u-PAR gene (Figure 1C).
However, the most striking observation was dissoci-
ation of the histone variant H2A.Z from the promoter
and enhancer region but not from intron 3 upon PMA
stimulation of u-PAR gene expression (Figure 1C). Note
that a recent study indicates that there are two H2A.Z
isoforms: H2A.Z-1 and H2A.Z-2 (40,41) with most
studies to date evaluating the product of the H2A.Z-1
gene. The data presented here evaluate the role of
H2A.Z-1 (H2A.Z) in u-PAR regulation.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 601To determine if H2A.Z loss associated with activation
of u-PAR gene expression was a generalized response, or
unique to GEO cells, we also performed ChIP with two
other cell lines (A2780 and OVCAR3—both ovarian
cancer derived). Like GEO cells, both A2780 and
OVCAR3 showed a dramatic loss of H2A.Z from both
u-PAR regulatory regions on induction of gene expression
(Figure 1D and E). The possibility that the observed
Figure 1. u-PAR transcription and H2A.Z deposition at the u-PAR promoter/enhancer are inversely correlated. (A) Schematic representation of the
u-PAR gene indicating ChIP-Q-PCR amplicons. (B) qPCR showing u-PAR upregulation in response to PMA treatment (4h) in GEO cells. (C) ChIP
analysis showing the relative enrichment of various histone modiﬁcations and H2A.Z at the u-PAR promoter, enhancer and intron 3 upon PMA
stimulation (4h) compared to untreated samples. (D) qPCR showing u-PAR mRNA upregulation in response to PMA treatment (4h) in A2780 and
OVCAR3 cells. (E) ChIP assay of H2A.Z deposition at the u-PAR regulatory regions and intron 3 upon PMA induction (4h) in A2780 and
OVCAR3 cells. (F and G) qPCR (F) and ChIP assay (G) illustrates that u-PAR expression and H2A.Z deposition at the u-PAR-regulatory regions in
response to PMA mirror each other but in the opposite direction. Data represent average (± SD) values of six separate determinations. The relative
enrichment of protein in all ChIP assays was calculated as 2
Ct where Ct=Ct (Input)-Ct (ChIP). All qRT–PCR data are normalized using
GAPDH as an internal control.
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gene was due to changes in nucleosome density is unlikely
since the deposition of histone H3 at these regions showed
negligible change upon PMA stimulation (Supplementary
Figure S1A). Additionally, there was no change in the
total amount of H2A.Z upon PMA induction (data not
shown). Furthermore, the H2A.Z occupancy at a control
(GAPDH) promoter was unaffected by PMA stimulation
(Supplementary Figure S1B).
Next, to investigate the dynamics of the interaction of
H2A.Z with the u-PAR promoter/enhancer and its
relation to gene expression we performed a time course
study with PMA. Modulation of u-PAR mRNA levels
was cyclic with GEO cells peaking at 4h and diminishing
at 10h before increasing again (Figure 1F). Interestingly,
the occupancy of the u-PAR promoter/enhancer with
H2A.Z was also cyclic although in the opposite direction
(Figure 1G), such that maximal u-PAR mRNA levels at
4h was associated with the greatest loss of H2A.Z.
Conversely at 10h post-PMA stimulation, a return of
u-PAR mRNA levels almost to baseline was associated
with recruitment of H2A.Z to the promoter and
enhancer. Taken together, the results suggest that the oc-
cupancy by H2A.Z is inversely correlated with u-PAR
mRNA levels.
H2A.Z is preferentially enriched proximal to transcription
factor-binding sites at the u-PAR promoter and enhancer
To map the regions of H2A.Z enrichment, we performed
ChIP and tiled qPCR to interrogate various u-PAR
genomic regions both upstream and downstream of the
major transcriptional start site (Figure 2). Studies from
our and other laboratories had previously identiﬁed
several cis- and trans-acting factors regulatory for
u-PAR transcription (Figure 2A) residing both upstream
(e.g. AP-1, AP-2 and NFkB) of the transcriptional start
site and downstream (AP-1) embedded in the intron 1
enhancer (21,30–33). Interestingly, H2A.Z was preferen-
tially enriched proximal to these previously implicated
Figure 2. H2A.Z preferentially occupies the regulatory regions of u-PAR.( A) Schematic representation of the u-PAR promoter and intron 1 (which
contains the enhancer) with ChIP-Q-PCR amplicons depicted. Various upstream transcription factor binding sites are shown. (B) Mapping of H2A.Z
deposition in the absence, or presence, of PMA (4h) at the various u-PAR regions. Various amplicons (e.g. P1, P2) and their genomic positions with
reference to the transcription start site are marked in the ﬁgure. Data are shown as average values of six separate determinations (±SD). Relative
enrichments are calculated as described in Figure 1.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 603transcription factor-binding sites within the u-PAR
promoter (P1–P3 region) and enhancer (In4 region,
Figure 2B and Supplementary Figure S2). At intron 1,
H2A.Z was deposited around the enhancer region (at
region In3 and In4) but not at the 30-end of this intron
(In5–In8, Supplementary Figure S2). Equally important,
on PMA stimulation, H2A.Z speciﬁcally dissociated from
both regulatory regions enriched for H2A.Z (P1–P3 and
In4, Figure 2B) although levels were essentially unchanged
in the regions either upstream (P4–P7) of the promoter or
downstream of the enhancer region (In8 and In11,
Figure 2B). The selective enrichment and loss (upon
stimulation of gene expression) at these loci argue for a
regulatory role of H2A.Z in u-PAR expression.
Depletion of cellular H2A.Z upregulates u-PAR
expression
H2A.Z has been shown to regulate gene expression both
positively and negatively (42–45). In order to determine
the role of H2A.Z in u-PAR regulation, we knocked down
H2A.Z in three independent cell lines (GEO, A2780 and
OVCAR3) using siRNA (Figure 3A and Supplementary
Figure S3). Interestingly, cellular depletion of H2A.Z
resulted in upregulated u-PAR mRNA level in all three
cell lines (Figure 3A). Data were normalized with
GAPDH which itself was not affected by H2A.Z
knockdown. Western analysis done with GEO cells con-
ﬁrmed these data (Supplementary Figure S3). ChIP assays
conﬁrmed that reduced amounts of H2A.Z were deposited
at these two regulatory regions in cells repressed for
H2A.Z mRNA (Figure 3B). If PMA is inducing u-PAR
expression by way of H2A.Z eviction then depletion of the
latter should interfere with the ability of the phorbol ester
to stimulate u-PAR expression. Indeed, while H2A.Z de-
pletion of GEO cells induced (P<0.005) u-PAR expres-
sion to the level observed with PMA alone (Figure 3C)
there was no further enhancement of u-PAR expression
when H2A.Z-depleted cells were treated with the phorbol
ester (Figure 3C). Overall, these results suggest that
H2A.Z negatively regulates u-PAR transcription.
MEK–ERK signaling intersects with the epigenetic
control of u-PAR expression by H2A.Z
PMA mediates its effects by mimicking diacylglycerol
(DAG), the endogenous activator of protein kinase C
(PKC) the latter activating the MEK–ERK signaling
pathway (Figure 4A). Since PMA treatment had resulted
in the rapid eviction of H2A.Z from the u-PAR regulatory
regions we speculated that the PKC–MEK–ERK signal-
ing pathway (Figure 4A) intersects with the epigenetic
control of u-PAR expression by H2A.Z. Pre-treatment
of GEO cells with 10mM Bisindolylmaleimide III
Figure 3. H2A.Z negatively regulates u-PAR expression. (A) qPCR using H2A.Z and u-PAR Taqman probes were performed using cDNA generated
from three independent cell lines (GEO, A2780 and OVCAR3) transfected with 25nM of a non-silencing siRNA (control) or an H2A.Z-speciﬁc
siRNA for 48h. Data are normalized using GAPDH as an internal control. (B) ChIP assay with H2A.Z-repressed GEO cells reveals reduced H2A.Z
deposition at the u-PAR gene under the conditions speciﬁed in Panel A. (C) qPCR using u-PAR Taqman probe was performed using cDNA
generated from GEO cells transfected with 25nM of a non-silencing siRNA (control) or an H2A.Z-speciﬁc siRNA for 48h before 30min PMA
treatment (as indicated). Data are shown as average values of six separate determinations (± SD). Statistical signiﬁcance was tested using Student’s
unpaired t-test and the level of signiﬁcance was as follows: *P< 0.010, **P<0.005.
604 Nucleic Acids Research, 2012,Vol. 40,No. 2Figure 4. MEK–ERK signaling intersects with H2A.Z-mediated epigenetic control of u-PAR expression. (A) Schematic representation of the MEK–
ERK signaling pathway. (B–J) qPCR analysis of u-PAR mRNA levels and ChIP analysis of H2A.Z deposition at the u-PAR promoter/enhancer and
intron 3 from GEO cells pretreated for 2h with the following inhibitors BIM (10mM) (B and C), PD98509 (60mM) (D and E), U0126 (20mM) (F and
G), SB203580 (2mM) (H and J), SP600125 (20mM) (I, J) before the addition of 100nM PMA for 1h. (K and L) qPCR analysis of u-PAR mRNA (K)
and ChIP analysis for H2A.Z deposition at the u-PAR promoter/enhancer and intron 3 (L) from RKO cells treated for 4h with BIM and PD98509
inhibitors using the conditions speciﬁed in Panels B and C. All q-RT–PCR data are normalized using GAPDH as an internal control. Data reﬂect
average (±SD) values of at least six separate determinations. Statistical signiﬁcance was tested using the Student’s unpaired t-test and the level of
signiﬁcance was as follows: *P<0.05, **P<0.005.
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PKC, completely blocked PMA-induced mRNA expres-
sion of u-PAR but had no effect on basal mRNA level
(Figure 4B). Interestingly, ChIP assays indicated that
BIM III treatment also diminished the PMA-driven dis-
sociation of H2A.Z from the u-PAR promoter and
enhancer (Figure 4C). Next, we used two highly speciﬁc
inhibitors of MEK–ERK signaling, PD98059 (60mM) and
U0126 (20mM). Pretreatment of GEO cells with either of
these inhibitors blocked the PMA-induced u-PAR expres-
sion (Figure 4D and F) and considerably attenuated the
PMA-mediated dissociation of H2A.Z from the u-PAR
promoter and enhancer region (Figure 4E and G). Next,
we queried the involvement of two other MAP-kinase
pathways which can also be activated by PMA.
SB203580 speciﬁcally blocks the p38 pathway and
SP600125 targets the JNK pathway. Pre-treatment of
GEO cells with either of these inhibitors had little effect
on the ability of PMA to augment u-PAR mRNA levels or
promote H2A.Z dissociation from the u-PAR promoter
and enhancer regions (Figure 4H–J). In summary, our
data are consistent with the idea that MEK–ERK signal-
ing regulates H2A.Z deposition at the u-PAR regulatory
regions.
We then determined the effect of BIM III and PD98059
on u-PAR mRNA levels/H2A.Z deposition in a colon
cancer cell line (RKO) which intrinsically shows a high
transcription rate of u-PAR (21). Consistent with our
previous ﬁndings, both PKC and MEK1/2 inhibitors
(BIM III and PD98059) attenuated u-PAR mRNA levels
coincident with increased deposition of H2A.Z at the
promoter/enhancer regions but not at intron 3
(Figure 4K and L).
Expression of a mutation-activated K-Ras (G12V) induces
u-PAR expression and stimulates H2A.Z dissociation
from the promoter/enhancer
K-Ras is activated in many cancers contributing to
tumorigenesis and progression (46–48). Moreover
signaling of K-Ras through the MEK–ERK pathway is
well established and our current and previous work
demonstrated that u-PAR expression is increased by this
oncogene (Figure 5A) (27,46–49). Consequently, using
transient transfection assays, we then determined the
effect of expressing an activated K-Ras (G12V) construct
on u-PAR expression and H2A.Z deposition at the u-PAR
regulatory regions in GEO cells. u-PAR expression was
increased by overexpression of the mutation-activated
K-Ras compared with the empty vector control
(Figure 5A) concordant with reduced amounts of H2A.Z
bound to the endogenous u-PAR promoter and enhancer
(Figure 5B). This result further supports the notion that
u-PAR transcription and H2A.Z deposition at the u-PAR-
regulatory regions is modulated by the Ras-raf-MEK–
ERK signaling pathway.
Trans-activation of the u-PAR gene by AP-1 is required
for H2A.Z eviction
Our next goal was to determine how the MEK–ERK
pathway regulated the loss of H2A.Z from the u-PAR
regulatory regions. We speculated on a role for AP-1
since (i) the MEK–ERK signaling pathway regulates the
activity/amount of AP-I family transcription factors
(49,50) (ii) our previous studies showed that constitutive
and PMA-inducible expression of u-PAR required two
AP-1 motifs in the promoter region (21) and one in the
downstream enhancer (33) (iii) of the transcription factors
implicated in u-PAR expression, only AP-1 was common
to both promoter and enhancer. Accordingly, we ex-
pressed the TAM-67 expression construct, encoding a
c-Jun protein lacking its trans-activation domain (and
therefore acting in a dominant negative fashion) in GEO
cells and then treated the cells with PMA. Our data dem-
onstrate that PMA-induced u-PAR mRNA level was ef-
fectively countered by expression of this construct
compared to the empty vector control (Figure 6A).
Equally important, in ChIP assays, expression of
TAM-67 largely reversed the PMA-driven H2A.Z
Figure 5. Overexpression of a constitutively active, mutation-activated K-Ras modulates H2A.Z deposition. (A) The indicated amount of the empty
vector (vector-control) or the mutation-activated K-Ras (G12V) encoding vector was transiently transfected into GEO cells for 48h and qPCR
performed to measure u-PAR mRNA expression. (B) Under parallel conditions, ChIP analysis was performed to quantify the amount of H2A.Z
deposited at the indicated u-PAR genomic regions. Data are shown as average values (±SD) of six separate determinations. The Student’s unpaired
t-test and the level of signiﬁcance were as follows: *P<0.05; **P<0.005. All qRT–PCR data were normalized with GAPDH as an internal control.
606 Nucleic Acids Research, 2012,Vol. 40,No. 2Figure 6. Trans-activation by AP-1 is a prerequisite for H2A.Z depletion at the u-PAR promoter/enhancer. (A) qPCR was performed to measure
u-PAR mRNA expression in GEO cells transiently transfected with the indicated amount of the vector-control or Tam-67 for 24h and then treated,
where indicated, with PMA for 1h. (B) Under parallel conditions, ChIP assays revealed that expression of Tam-67 attenuated PMA-induced H2A.Z
eviction from the u-PAR promoter and enhancer. (C) qPCR quantitation of u-PAR mRNA level and (D) ChIP analysis of H2A.Z deposition at
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(continued)dissociation from the u-PAR promoter and enhancer
regions (Figure 6B). This result is consistent with the
notion that AP-1-dependent trans-activation is required
for H2A.Z eviction and u-PAR expression.
PMA has also been shown to induce NFkB (51,52), the
latter implicated in u-PAR regulation (32). So next, we
determined whether inhibition of NFkB affects the
dynamics of H2A.Z interaction with the u-PAR-regula-
tory regions. Interestingly, Caffeic acid phenethyl ester
(CAPE), a speciﬁc inhibitor of NFkB (but not AP-1)
(53) while blocking PMA-induced u-PAR expression had
no effect on the PMA-driven dissociation of H2A.Z
(Figure 6C and D). This result indicates that NFkBi s
not involved in regulating H2A.Z deposition at the
u-PAR promoter/enhancer.
Hypoxia also upregulates u-PAR expression via binding
of HIF-a to the hypoxia response element (HRE) located
within the u-PAR promoter (30). u-PAR expression was
upregulated when GEO and A2780 cells were exposed to
24h hypoxia (0.2%) (Figure 6E and F); however there was
no accompanying change in H2A.Z occupancy at the
u-PAR promoter (Figure 6E and F). Taken together, the
data suggest that H2A.Z eviction is not a generalized re-
quirement for transactivation of the u-PAR gene.
We also entertained the possibility that H2A.Z eviction
was a consequence of increased transcription rather than a
cause. To address this possibility we made use of
a-amanitin which blocks transcription by RNA polymer-
ase II (RNAP II). Treatment of GEO cells with 10mMo f
a-amanitin almost completely inhibited PMA-induced ex-
pression of u-PAR (Figure 6G). However, strikingly,
parallel ChIP assays revealed that inhibition of
PMA-induced transcription by a-amanitin did not affect
the phorbol ester-driven loss of H2A.Z from the promoter
or enhancer regions (Figure 6H). This result unambigu-
ously shows that H2A.Z eviction is not secondary to
RNAP II processivity.
AP-1 transactivation precedes H2A.Z remodeling
If AP-1 transactivation is required for H2A.Z eviction in
turn leading to u-PAR gene expression then chip experi-
ments should demonstrate such a temporal sequence.
Accordingly, we performed ChIP assays using chromatin
generated from GEO cells treated with PMA for varying
times. These experiments revealed a statistically signiﬁcant
increase in binding of AP-1 (using a mixture of anti c-fos/
phosopho-c-jun antibodies) at the u-PAR promoter and
enhancer as early as 15-min post-PMA addition
(Figure 7A). In contrast, H2A.Z dissociation (Figure 7B)
and enrichment of processive RNA Polymerase II
(Figure 7C) lagged being ﬁrst evident after 30min of
phorbol ester treatment. Taken together, these results
suggest that binding of AP-1 at the u-PAR promoter/
enhancer precedes H2A.Z eviction and transcription
initiation.
H2A.Z regulates MMP-9 and oncomiR-21 transcription
To determine whether H2A.Z dissociation was also per-
tinent to the regulated expression of other AP-1 targets,
we undertook studies with the MMP-9 gene and miR-21
micro-RNA which are also regulated by PMA (54–58).
OVCAR3 cells express low levels of MMP9 mRNA but
was induced 10- to 30-fold by PMA (Figure 8B).
Figure 6. Continued
the u-PAR promoter/enhancer and intron3 from GEO cells pretreated for 2h with CAPE before the addition of 100nM (ﬁnal concentration) PMA
for 1h. (E and F) qPCR assay showing that hypoxia (24h) induces u-PAR expression (E) but does not affect the H2A.Z deposition (F) at the u-PAR
promoter in ChIP assays performed in two independent cell lines (GEO, A2780). (G and H) qPCR analysis showing a-amanitin (10mM), inhibits
PMA-inducible u-PAR expression (G); however PMA-driven eviction of H2A.Z from the u-PAR promoter/enhancer is not abrogated (H) as
evidenced in ChIP assays undertaken with GEO cells. Data are shown as average (± SD) values of six separate determinations. The Student’s
unpaired t-test and the level of signiﬁcance were as follows: *P<0.01. All qRT–PCR data are normalized with GAPDH as internal control except
for hypoxic conditions where Actin was used.
Figure 7. AP-1 binding to the u-PAR gene precedes H2A.Z eviction. ChIP assay showing the kinetics of (A) AP-1 (using a mixture of pan antibodies
directed against Fos and Jun family members) (B) H2A.Z (C) RNAP II (using an antibody against RNAP II phosphorylated at Serine 5) deposition
at the u-PAR promoter and enhancer in response to 100nm PMA for the indicated times. Data are shown as average values of six separate
determinations (±SD). The Student’s unpaired t-test was used to test for the level of signiﬁcance: *P<0.05; **P<0.02; ***P<0.0005 using time 0
as reference.
608 Nucleic Acids Research, 2012,Vol. 40,No. 2We mapped H2A.Z binding to the MMP-9 promoter in
PMA untreated/treated OVCAR3 cancer cells. H2A.Z
was enriched upstream of the MMP9 transcription start
site with peak binding in the P3 region coincident with the
distal AP-1 site shown previously by us to be regulatory
for expression (Figure 8A and C). Moreover, on PMA
treatment, the amount of H2A.Z bound to the P1 and
P3 regions mapping to the proximal and distal AP-1
sites diminished to almost undetectable levels (Figure 8C
and D).
Similarly on PMA treatment, transcription of miR-21
was induced 2-fold and again H2A.Z was depleted from
the regions of the miR-21 promoter proximal to (P1–P4)
but not distal from (P5 and P6) the AP-1 sites
(Figure 8E–G). Furthermore, depleting of cellular
H2A.Z using siRNA in OVCAR3 cells induced the expres-
sion of both MMP-9 and miR-21 (Figure 8H). Our results
suggest that H2A.Z eviction from the regulatory regions is
a key step in the control of, at least, a subset of
AP-1-regulated targets.
DISCUSSION
Our study demonstrates a novel role of MEK–ERK sig-
naling in the epigenetic regulation of three AP-1 targets,
including u-PAR, via H2A.Z remodeling. H2A.Z is
Figure 8. H2A.Z remodeling at other AP-1-regulated targets. (A) Schematic representation of the MMP-9 upstream regulatory region with
amplicons generated by qPCR. (B) qPCR showing MMP-9 upregulation in response to PMA (4h) in OVCAR3 cells. (C) Mapping of H2A.Z
deposition in the absence, or presence, of PMA (4h) at the MMP-9 upstream region. (D) Image of the gel resolving ampliﬁcation products generated
as per Panel C (E) Schematic representation of the miR-21 promoter with Q-PCR amplicons. (F) qPCR showing miR-21 upregulation in response to
PMA (4h) in OVCAR3 cells. (G) Mapping of H2A.Z deposition in the absence, or presence, of PMA (4h) at the miR-21 promoter. (H) qPCR data
illustrating that H2A.Z knockdown (25nM of siRNA) induces expression of both MMP-9 and miR-21. Data are shown as average values (±SD) of
six separate determinations. The Student’s unpaired t-test was used to determine the level of signiﬁcance: *P<0.05; **P<0.01; ***P<0.005.
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latory regions of u-PAR, MMP-9 and miR-21 and activa-
tion of MEK–ERK signaling (either genetically by a
mutation-activated-K-Ras or chemically with phorbol
ester) leads to its dissociation culminating in gene activa-
tion. To our knowledge, our study is the ﬁrst to show
regulation of a protease family member or, for that
matter, any AP-1 target by H2A.Z.
H2A.Z has recently emerged as an epigenetic regulator
of transcription, representing the terminus of diverse sig-
naling systems including the glucocorticoid receptor (GR),
estrogen receptor (ERa) and p53 (42,43, 59). Similar to
our ﬁndings with AP-1, H2A.Z is enriched proximal to
GR DNA-binding sites within the regulatory regions of
target genes. Ligand binding to the corresponding
receptor results in H2A.Z eviction at GR-inducible genes
(59). In a similar vein, H2A.Z co-localizes with p53-
binding sites at its downstream target, the p21 promoter,
and again its dissociation is associated with gene activa-
tion (43). However, in some instances, H2A.Z accrual,
rather than depletion, at target gene regulatory regions
is correlated with augmented expression. Thus, deposition
of this histone variant at ERa-targeted gene promoters
including TFF1 is coincident with activation of gene ex-
pression (43).
While our work demonstrated H2A.Z as repressive for,
at least, a subset of AP-1-trans-activated genes, others
have reported that macro H2A (another histone variant)
is also targeted by this family of transcription factors
culminating in altered gene expression. Thus, AP-1
recruits macroH2A to suppress gene transcription from
the IL-6 promoter (60). Although the ﬁndings of histone
variants as regulatory for a subset of AP-1-controlled
genes is novel, modulation of AP-1-responsive genes
through post-translational modiﬁcation of canonical
histones has been well studied. As one example, Miotta
and co-workers (2006) reported that histone H4 acetyl-
ation enhances the ability of AP-1 to trans-activate
target genes in Drosophila (61). Similarly, histone acetyl-
ation and phosphorylation associated with increased oc-
cupancy of AP-1 motifs with JunB, JunD and c-Fos
culminates in the stimulation of MMP-9 expression by
PMA (62).
H2A.Z shows a preference for DNA-ase hypersensitive
sites the latter often characteristic of regulatory regions i.e.
promoters and enhancers (43, 59,63). In our study on the
u-PAR gene, H2A.Z accrual or depletion at the promoter
and enhancer were synchronized under conditions of gene
activation or repression. Similarly, recruitment of GR to
target genes resulted in H2A.Z eviction from both enhan-
cers and promoters (59). It may be that under stimulatory/
repressive conditions, both promoter and enhancer are
juxtaposed by DNA looping bringing them into proximity
with a common H2A.Z exchange machinery. However,
this congruence in H2A.Z binding to promoter/enhancer
is not universal and examples of asynchronous H2A.Z
promoter/enhancer binding exist. For instance, while
H2A.Z is enriched at ERa targeted gene enhancers, it is
depleted from the ERa promoters of the same genes under
repressive conditions. Conversely, gene activation is
associated with depletion from the enhancer but enrich-
ment at the promoter of these genes (e.g. TFF1) (43).
There is a paucity of studies linking signaling modules
to the regulation of gene expression by non-canonical
histones. To our knowledge, the only other study address-
ing this question implicated p38 MAPK signaling in the
epigenetic regulation of muscle speciﬁc genes (64). In that
study, p18
hamlet /SRCAP-mediated H2A.Z incorporation
at muscle gene promoters was controlled by p38 MAPK
signaling. This epigenetic regulation of gene expression
was the key to the expression of a muscle
differentiation-speciﬁc gene program. This latter study
parallels ours in establishing, for the ﬁrst time, a direct
link between MEK–ERK signaling and epigenetic regula-
tion, via H2A.Z, of several AP-1 targets.
While the concept of non-canonical histones as targets
of signaling pathways is relatively new, the link between
MEK–ERK signaling and epigenetic control of gene ex-
pression via conventional histones (H1–H4) is well
investigated (34,65,66). However, the variant and conven-
tional histones show a signiﬁcant difference in their modes
of regulation. Thus, while exchange of variant histones
represents the major mechanism for regulating gene ex-
pression, in contrast, post-transcriptional modiﬁcation of
S phase-synthesized (i.e. conventional) histones is the pre-
dominant mechanism by which gene expression is
achieved. By way of example, MEK–ERK signaling ter-
minates at MSK1/2 H3 kinase the latter mediating the
phosphorylation of H3 histone at Serine 10 or 28 at im-
mediate/early genes promoters to induce their expression
(34,65,66). In another study, this signaling module was
also reported to suppress tumor suppressor protein Cbp
[C-terminal Src kinase (Csk)-binding protein] expression
via modulating histone modiﬁcations (H4 acetylation,
H3K27me3) (37). However, it is important to emphasize
the possibility that these modes of regulation may not be
mutually exclusive. It may be that post-translational
modiﬁcations of canonical histones cooperate, positively
or negatively, with the exchange of histone variants to
effect a change in gene expression. Certainly, our
previous work (33) demonstrated the u-PAR enhancer in
u-PAR-expressing colon cancer cells to be engaged by
acetylated/K4-methylated histone 3 under conditions of
gene activation.
The MEK–ERK signaling pathway is involved in a
multitude of biological events including cell proliferation,
cell cycling and wound healing, physiological events
commonly co-opted in malignancy/tumor progression
(67,68). Moreover, this pathway is aberrantly activated
in many cancers and sometimes at high frequency (47)
and recent reports have documented H2A.Z depletion
again associated cancer progression (69–72).
Furthermore, a recent report found a gain of acetylated
H2A.Z at the transcription start site despite an overall
decrease in H2A.Z levels, in concert with oncogene acti-
vation in cancer cells (73). These reports together with our
ﬁndings that the MEK–ERK pathway intersects with
H2A.Z-mediated repression of a subset of
AP-1-regulated genes raises the possibility that the node
at which these two systems intersect represents a novel
therapeutic target in cancer.
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